**GENE THERAPIES CAN BRING HOPE TO PATIENTS**
Reducing Treatment Burden and Costs

**Blood disorders** often require lifelong treatment involving routine drug infusions or blood transfusions. They can also be associated with frequent visits to physician offices, infusion centers or even the emergency room. Patients with these disorders often experience debilitating pain, disability, reduced life expectancy and quality of life.

Potential gene therapies may offer long-term benefits and even cures for patients with blood disorders with a single administration. Since they may drastically reduce the burden of the current standard of care, they may also:

- Reduce the need for patients to miss work for treatment and/or symptoms, leading to economic benefits for patients
- Dramatically reduce existing treatments for patients
- Result in savings for the health care system

### Current Standard of Care for Patients with Severe Disease

<table>
<thead>
<tr>
<th>Condition</th>
<th>Factor Replacement Therapy</th>
<th>Current Annual Health Care Costs Per Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEMOPHILIA A</td>
<td>Factor replacement therapy 2 to 3 times a week</td>
<td>As much as $760,000</td>
</tr>
<tr>
<td>HEMOPHILIA B</td>
<td>Factor replacement therapy 2 to 3 times a week</td>
<td>$615,000</td>
</tr>
<tr>
<td>BETA THALASSEMIA</td>
<td>17 blood transfusions a year, on average</td>
<td>$125,000</td>
</tr>
</tbody>
</table>

### Benefits of Gene Therapy

- Almost complete reduction in factor replacement therapy
- Almost complete reduction in factor replacement therapy
- Elimination of dependence on blood transfusions

### Potential Savings to the Health Care System the Year Following Gene Therapy Per Patient

- As much as $730,000
- As much as $600,000
- As much as $125,000

### Potential Annual Increase in Patient Income From Greater Workforce Participation

- As much as $9,500
- As much as $7,000
- As much as $4,000

*Figures reflect average costs, rounded up.*

For more on the analysis, visit PhRMA.org/Blood-Disorders
HEALTH EQUITY CASE STUDY: SICKLE CELL DISEASE

The Disease
Sickle cell disease is a rare blood disorder affecting 1 out of every 365 Black or African Americans. The disease causes crescent-shaped blood cells to clog blood vessels, which prevents the normal flow of nutrition and oxygen throughout the body and can lead to serious complications, including pain crisis and acute chest syndrome.

The Health Impact on Patients
Patients are hospitalized more than once a year, on average, and visit the emergency room 2 to 3 times a year, most commonly due to pain crisis. For people living with sickle cell disease, 50% report pain on half of their days and 30% report pain most of the time.

The Economic Impact on Patients
50% to 60% of patients reported the disease negatively impacted their employment status, forced them to stop working completely or take a leave of absence, or led to unpaid time off or reduced work hours. As a result, patients are estimated to earn $750,000 less over a lifetime, representing a significant burden on the Black and African American community disproportionately impacted by this disease.

The Treatments in the Pipeline
Gene therapies in the late stages of development have demonstrated an almost complete reduction in pain crisis.

The Benefit to Patients
By virtually eliminating the impact of this painful disease, gene therapy has the potential to dramatically reduce income disparities, leading to as much as $21,000 more in average income in the year following gene therapy administration alone.

While many gene therapies are administered just one time with long-lasting or even potentially curative effects, the full value they provide to patients, caregivers and the entire health care system may only be realized over the lifetime of the patient. Addressing the unique challenges presented by these groundbreaking therapies that offer the potential to transform health care requires a rethinking of the current reimbursement system to adapt and evolve to account for the long-term value these therapies provide.

For more on the analysis, visit PhRMA.org/Blood-Disorders